Clinical Trials Logo

Bradycardia clinical trials

View clinical trials related to Bradycardia.

Filter by:

NCT ID: NCT00266682 Completed - Bradycardia Clinical Trials

Clinical Investigation of the SelectSecure Pacing Lead

Start date: August 2002
Phase: N/A
Study type: Interventional

People who have a slow heart beat, or whose heart does not beat on its own, may be in need of an electronic device called a pacemaker. A pacemaker is implanted surgically just under the skin in the upper chest area. This device helps the heart beat at a regular rhythm by sending electrical signals (pacing) directly to the heart tissue through flexible wires called leads. The purpose of this study is to demonstrate that the SelectSecure (Model 3830) lead is safe and effective for both sensing the heart’s natural rhythm and pacing the heart when it does not beat on its own. This lead will be studied in both the right atrium and right ventricle. A previously market approved Medtronic lead model will serve as a comparison to prove the safety and effectiveness of the SelectSecure Model.

NCT ID: NCT00180609 Completed - Bradycardia Clinical Trials

SCANCAP Scandinavian Automatic Capture Study

Start date: December 2003
Phase: Phase 4
Study type: Observational

The primary objective of this study is to document the success rate of the automatic threshold testat pre-discharge in a normal pacemaker patient population implanted with Guidant Insignia Ultra or AVT .

NCT ID: NCT00180557 Completed - Bradycardia Clinical Trials

Austria Study - Analysis of Difference Between Active and Passive Fixation Leads

Start date: September 2003
Phase: Phase 4
Study type: Interventional

In this study the difference between screw in leads actively fixed in the septum and tined leads passively fixed in the apex concerning electrical parameters and implantation time will be evaluated. In addition the influence of the stimulation location by type of lead on QRS width, ejection fraction and NYHA class will be evaluated using and electrocardiogram and echocardiogram.

NCT ID: NCT00180284 Completed - Bradycardia Clinical Trials

SITELINE 2 Polyurethane

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The SITELINE 2 Polyurethane Clinical Investigation analyzed the safety and electrical performance of the SITELINE 2 Polyurethane pacing lead.

NCT ID: NCT00158925 Completed - Clinical trials for Congestive Heart Failure

The EASYTRAK EPI Clinical Investigation

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of the EASYTRAK EPI lead.

NCT ID: NCT00146861 Completed - Bradycardia Clinical Trials

LIFE Study - Limiting Chronotropic Incompetence for Pacemaker Recipients

Start date: July 2003
Phase: Phase 4
Study type: Interventional

This study will compare how two different sensors inside the pacemaker may affect patients' quality of life.

NCT ID: NCT00133289 Completed - Bradycardia Clinical Trials

ULTRA Study for Pacemaker Patients

Start date: July 2005
Phase: Phase 4
Study type: Interventional

The ULTRA study will assess the difference in average ventricular voltage output for pacemaker patients randomized to Automatic Capture feature ON versus patients randomized to Automatic Capture feature OFF.

NCT ID: NCT00123344 Completed - Atrial Fibrillation Clinical Trials

Atrial Pacing for Termination and Prevention of Atrial Fibrillation

Start date: December 1999
Phase: N/A
Study type: Interventional

Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with substantial morbidity and mortality. Present treatment strategies are aimed at termination of AF and prevention of AF recurrence using antiarrhythmic drugs or heart rate control drugs. Drugs are not always well tolerated, so atrial pacing as a strategy for prevention of atrial tachyarrhythmias is being explored. The AT501 pacemaker has both "prevention" and "treatment" algorithms for atrial tachyarrhythmias. The investigators wish to determine whether these special features, over the long term, decrease the amount of time the person experiences AF.